Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sisram Medical Ltd. ( (HK:1696) ) just unveiled an update.
Sisram Medical has signed a non-binding memorandum of understanding with Sinmait Medical Technology (Beijing) Co., Ltd., an indirect wholly owned subsidiary of its controlling shareholder Shanghai Fosun Pharmaceutical, to explore establishing local manufacturing for its energy-based medical devices in China. The proposed cooperation would shorten supply chains, enhance local responsiveness, and position China as a regional production and logistics hub for the Asia-Pacific market, but any resulting arrangements could constitute notifiable and connected transactions under Hong Kong listing rules and remain subject to definitive agreements and further regulatory announcements.
The most recent analyst rating on (HK:1696) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.
More about Sisram Medical Ltd.
Sisram Medical Ltd., incorporated in Israel and listed in Hong Kong, operates in the medical technology sector with a focus on energy-based medical devices. The Group targets core strategic markets including the People’s Republic of China and the broader Asia-Pacific region, aiming to expand its manufacturing and logistics capabilities to better serve growing regional demand.
Average Trading Volume: 566,570
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.03B
For a thorough assessment of 1696 stock, go to TipRanks’ Stock Analysis page.